Although mortality rates have been declining, prostate cancer accounts for a large percentage of cancer diagnoses around the world. Sipuleucel-T (Provenge®), an autologous cellular immunotherapy targeted against the antigen expressed in most prostate cancers, has been shown to increase the median survival rate of castration-resistant prostate cancer. Even so, the therapeutic risks and benefits, as well as financial implications, all currently play a role in the governmental decision to reimburse for this new therapy.
Porter C, Ilenin J, Berni L, Overy A, Kier KL. Sipuleucel-T (Provenge®): Therapeutic Use and Financial Implications. PAW Review. 2011 May 01; 2(2):Article 20 39-41 . Available from: https://digitalcommons.onu.edu/paw_review/vol2/iss2/20.